Previous 10 | Next 10 |
[[AEL]], [[ALB]], [[ALSN]], [[AM]], [[AR]], [[AXTA]], [[BCOV]], [[BFAM]], [[BIDU]], [[CAKE]], [[CDE]], [[CF]], [[CONE]], [[CYH]], [[ET]], [[FCPT]], [[FSLY]], [[GMED]], [[H]], [[HLF]], [[HPP]], [[IAG]], [[IQ]], [[JACK]], [[KAI]], [[LASR]], [[LOPE]], [[MANT]], [[MOS]], [[MRO]], [[MX]], [[NTR]],...
PLEASANTON, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2020 after market close on Wednesday, February 17, 2021. The company’s management will webcast a c...
Biotechnology companies that specialize in niche segments like genomics, cell-technology and genetic analysis are likely to see major upside in their stocks in the near-term. With increasing numbers of studies and advanced research, these companies are set to achieve major milestones. 10X GEN...
PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39 th Annual J.P. Morgan Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, January 11 ...
Though 10x Genomics has carved a niche in the single-cell genomics analysis industry, it has yet to report a profit since its inception in 2012. Its Q3 2020 sales zoomed because recently reopened labs rushed to consume their NIH funding. The company is expected to leak operating c...
10X Genomics is a cutting edge, single-cell assay hardware, software and consumables company. Don't feel bad, I don't understand all of that either. The company's systems are widely adopted, and shared use in labs is leading to further market penetration and growth. While hardware...
AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide. ABCL has grown from a small base but the IPO appears highly priced, so I'll pass on it. For further details see: AbCellera...
Dan Loeb's 13F portfolio value increased from ~$7.30B to ~$10B this quarter. The number of positions increased from 36 to 47. Third Point added PG&E while dropping Baxter International and Raytheon Technologies during the quarter. The top three positions are at ~22% of the por...
10X Genomics, Inc. (TXG) Q3 2020 Earnings Conference Call November 10, 2020, 17:00 ET Company Participants Eric Jaschke - Director, Investor Relations and Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Justin McAnear - CFO Bradford Crutchfield - Chief Commercial Officer Conf...
10x Genomics, Inc. (TXG) Q3 2020 Results Conference Call November 9, 2020 4:50 PM ET Company Participants Eric Jaschke - Director of Investor Relations and Strategic Finance Serge Saxonov - Co-Founder & Chief Executive Officer Justin McAnear - Chief Financial Officer Bradford Crutchfield ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...